Fidia Pharma Group expected to be a key player in the ophthalmic sector

The Company is finalizing the acquisition of Italian Sooft/Oox Group

As announced at the end of 2016, Fidia has finalized the first step to the successful acquisition of the majority stake in the Sooft/Oox Group, through a legally binding agreement that will be executed over the next few weeks.

Sooft/Oox is an Italian group active in the ophthalmic sector, with a product portfolio that includes several well-known brands, amongst them, Iridium e Blugel. The Group is positioned among the top four companies in this market segment, and is engaged in the development of products for all major eye diseases.

The acquisition of the Sooft/Oox Group will enable Fidia, who was active in the ophthalmology segment in previous years, to re-gain market share and strengthen its position in this area, offering products under various therapeutic categories, such as eye drops, nutraceuticals and medical devices.

Further updates and details will be provided as soon as the acquisition is executed.


Find out more about Fidia’s product portfolio:

Go to the website


Fidia Farmaceutici has a specific module dedicated to Pharmaco-Vigilance in order to promptly reporting of suspected adverse reactions. If you suspect that you have had an adverse reaction while taking one of our products or you have found defects

Key Business Areas

Fidia operates in numerous therapeutic areas, providing specific, innovative treatments for commonly occurring pathologies with major socio-economic impact, namely:

- joint care
- ophthalmology
- active wound care
- neuroscience
- aesthetic medicine